The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
A Placebo-Controlled Trial of Omega-3 Fatty Acid (Ethyl Eicosapentaenoic Acid) Supplementation for Residual Symptoms and Cognitive Impairment in Schizophrenia
Abstract
OBJECTIVE: This study determined if augmentation of neuroleptics with 3 g/day of ethyl eicosapentaenoic acid (EPA) improves symptoms and cognition in patients with schizophrenia or schizoaffective disorder. METHOD: Eighty-seven patients meeting criteria for schizophrenia or schizoaffective disorder who had residual symptoms despite neuroleptic treatment were randomly assigned to receive either 3 g/day of ethyl EPA (N=43) or placebo (N=44) in a 16-week, double-blind supplementation trial. Assessments were performed at baseline and at weeks 1, 2, 4, 8, 12, and 16; a cognitive battery was administered at baseline and at week 16. RESULTS: No differences were found between groups in positive or negative symptoms, mood, cognition, or global impression ratings. Results were similar for the intention-to-treat (N=87) and completer (N=75) groups. CONCLUSIONS: For schizophrenia patients treated with 3 g/day of ethyl EPA, improvement in residual symptoms and cognitive impairment was no greater than for schizophrenia patients treated with placebo.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Positive and Negative Syndrome Scale (PANSS) for schizophrenia.
Kay, S. R., Fiszbein, A., & Opler, L. A. (1987) · Schizophrenia Bulletin · doi:10.1093/schbul/13.2.261 · Cited by 21,378
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962
Reproducibility and validity of a semiquantitative food frequency questionnaire
WILLETT, W. C., SAMPSON, L., STAMPFER, M. J., ROSNER, B., BAIN, C., WITSCHI, J., HENNEKENS, C. H., & SPEIZER, F. E. (1985) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a114086 · Cited by 4,274
A RATING SCALE FOR EXTRAPYRAMIDAL SIDE EFFECTS
SIMPSON, G. M., B., M., B., G., ANGUS, J. W. S., P., F. R. C., & M., D. P. (1970) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1970.tb02066.x · Cited by 3,264
Lehman, A. F., Steinwachs, D. M., & The Co-Investigators of the PORT Project (1998) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a033302 · Cited by 910
One hundred years of schizophrenia: a meta-analysis of the outcome literature
(1994) · American Journal of Psychiatry · doi:10.1176/ajp.151.10.1409 · Cited by 762
Fenton, W. S., Hibbeln, J., & Knable, M. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00092-x · Cited by 328
Self-citationPeet, M., Laugharne, J. D. E., Mellor, J., & Ramchand, C. N. (1996) · Prostaglandins, Leukotrienes and Essential Fatty Acids · doi:10.1016/s0952-3278(96)90148-9 · Cited by 170
Puri, B. K., & Richardson, A. J. (1998) · Archives of General Psychiatry · doi:10.1001/archpsyc.55.2.188 · Cited by 71
Research works printed but not linked: 1
- National Institute of Mental Health: CGI (Clinical Global Impression) Scale. Psychopharmacol Bull 1985; 21:839-843
Cited by
Functional Roles of Fatty Acids and Their Effects on Human Health
Calder, P. C. (2015) · Journal of Parenteral and Enteral Nutrition · doi:10.1177/0148607115595980 · Cited by 1,160
Djuricic, I., & Calder, P. C. (2021) · Nutrients · doi:10.3390/nu13072421 · Cited by 1,015
Amminger, G. P., Schäfer, M. R., Papageorgiou, K., Klier, C. M., Cotton, S. M., Harrigan, S. M., Mackinnon, A., McGorry, P. D., & Berger, G. E. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2009.192 · Cited by 896
Omega-3 Fatty Acids: Evidence Basis for Treatment and Future Research in Psychiatry
Freeman, M. P., Hibbeln, J. R., Wisner, K. L., Davis, J. M., Mischoulon, D., Peet, M., Keck, P. E., Marangell, L. B., Richardson, A. J., Lake, J., et al. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n1217 · Cited by 709
Self-citationOmega-3 fatty acids in major depressive disorder
Su, K.-P., Huang, S.-Y., Chiu, C.-C., & Shen, W. W. (2003) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(03)00032-4 · Cited by 596
Grosso, G., Pajak, A., Marventano, S., Castellano, S., Galvano, F., Bucolo, C., Drago, F., & Caraci, F. (2014) · PLoS ONE · doi:10.1371/journal.pone.0096905 · Cited by 449
Essential Fatty Acids and the Brain
Haag, M. (2003) · The Canadian Journal of Psychiatry · doi:10.1177/070674370304800308 · Cited by 421
Very long-chain n -3 fatty acids and human health: fact, fiction and the future
Calder, P. C. (2018) · Proceedings of the Nutrition Society · doi:10.1017/s0029665117003950 · Cited by 419
Dietary fats and membrane function: implications for metabolism and disease
Hulbert, A. J., Turner, N., Storlien, L. H., & Else, P. L. (2005) · Biological Reviews · doi:10.1017/s1464793104006578 · Cited by 406
The Schizophrenia Prodrome Revisited: A Neurodevelopmental Perspective
Cornblatt, B. A., Lencz, T., Smith, C. W., Correll, C. U., Auther, A. M., & Nakayama, E. (2003) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a007036 · Cited by 377
Martins, J. G. (2009) · Journal of the American College of Nutrition · doi:10.1080/07315724.2009.10719785 · Cited by 358
n‐3 Omega fatty acids: a review of current knowledge
Gogus, U., & Smith, C. (2010) · International Journal of Food Science & Technology · doi:10.1111/j.1365-2621.2009.02151.x · Cited by 358
Appleton, K. M., Rogers, P. J., & Ness, A. R. (2010) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.2009.28313 · Cited by 353
Efficacy of Anti-inflammatory Agents to Improve Symptoms in Patients With Schizophrenia: An Update
Sommer, I. E., van Westrhenen, R., Begemann, M. J. H., de Witte, L. D., Leucht, S., & Kahn, R. S. (2014) · Schizophrenia Bulletin · doi:10.1093/schbul/sbt139 · Cited by 342
EFA supplementation in children with inattention, hyperactivity, and other disruptive behaviors
Stevens, L., Zhang, W., Peck, L., Kuczek, T., Grevstad, N., Mahon, A., Zentall, S. S., Eugene Arnold, L., & Burgess, J. R. (2003) · Lipids · doi:10.1007/s11745-006-1155-0 · Cited by 337
Cross-National Comparisons of Seafood Consumption and Rates of Bipolar Disorders
Noaghiul, S., & Hibbeln, J. R. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.12.2222 · Cited by 316
Self-citationOmega-3 fatty acids and antioxidants in neurological and psychiatric diseases: An overview
Mazza, M., Pomponi, M., Janiri, L., Bria, P., & Mazza, S. (2007) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2006.07.010 · Cited by 306
Intervention in Individuals at Ultra-High Risk for Psychosis: A Review and Future Directions
McGorry, P. D., Nelson, B., Amminger, G. P., Bechdolf, A., Francey, S. M., Berger, G., Riecher-Rössler, A., Klosterkötter, J., Ruhrmann, S., Schultze-Lutter, F., et al. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08r04472 · Cited by 305
Omega-3 fatty acids for the treatment of depression: systematic review and meta-analysis
Bloch, M. H., & Hannestad, J. (2012) · Molecular Psychiatry · doi:10.1038/mp.2011.100 · Cited by 293
Lewis, D. A., Cho, R. Y., Carter, C. S., Eklund, K., Forster, S., Kelly, M. A., & Montrose, D. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.08030395 · Cited by 292
Arvindakshan, M. (2003) · Schizophrenia Research · doi:10.1016/s0920-9964(02)00284-0 · Cited by 280
McGorry, P. D., Nelson, B., Goldstone, S., & Yung, A. R. (2010) · The Canadian Journal of Psychiatry · doi:10.1177/070674371005500803 · Cited by 279
Omega-3 fatty acids as treatments for mental illness: which disorder and which fatty acid?
Ross, B. M., Seguin, J., & Sieswerda, L. E. (2007) · Lipids in Health and Disease · doi:10.1186/1476-511x-6-21 · Cited by 275
Omega-3 fatty acids in ADHD and related neurodevelopmental disorders
Richardson, A. J. (2006) · International Review of Psychiatry · doi:10.1080/09540260600583031 · Cited by 267
Very long chain omega‐3 (n‐3) fatty acids and human health
Calder, P. C. (2014) · European Journal of Lipid Science and Technology · doi:10.1002/ejlt.201400025 · Cited by 265
Omega-3 Fatty Acids in the Treatment of Psychiatric Disorders
Peet, M., & Stokes, C. (2005) · Drugs · doi:10.2165/00003495-200565080-00002 · Cited by 258
Carbon, M., & Correll, C. U. (2014) · CNS Spectrums · doi:10.1017/s1092852914000601 · Cited by 258
Rogers, P. J., Appleton, K. M., Kessler, D., Peters, T. J., Gunnell, D., Hayward, R. C., Heatherley, S. V., Christian, L. M., McNaughton, S. A., & Ness, A. R. (2008) · British Journal of Nutrition · doi:10.1017/s0007114507801097 · Cited by 243
Antioxidants as potential therapeutics for neuropsychiatric disorders
Pandya, C. D., Howell, K. R., & Pillai, A. (2013) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2012.10.017 · Cited by 222
Jeppesen, R., Christensen, R. H. B., Pedersen, E. M. J., Nordentoft, M., Hjorthøj, C., Köhler-Forsberg, O., & Benros, M. E. (2020) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2020.08.028 · Cited by 132
Sinn, N., Milte, C., & Howe, P. R. C. (2010) · Nutrients · doi:10.3390/nu2020128 · Cited by 115
An Open Study of Sulforaphane-rich Broccoli Sprout Extract in Patients with Schizophrenia
Shiina, A., Kanahara, N., Sasaki, T., Oda, Y., Hashimoto, T., Hasegawa, T., Yoshida, T., Iyo, M., & Hashimoto, K. (2015) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2015.13.1.62 · Cited by 107
Peet, M. (2003) · Prostaglandins, Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2003.08.020 · Cited by 103
Sivrioglu, E. Y., Kirli, S., Sipahioglu, D., Gursoy, B., & Sarandöl, E. (2007) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2007.07.004 · Cited by 102
Current Clinical Applications of Ω‐6 and Ω‐3 Fatty Acids
Lee, S., Gura, K. M., Kim, S., Arsenault, D. A., Bistrian, B. R., & Puder, M. (2006) · Nutrition in Clinical Practice · doi:10.1177/0115426506021004323 · Cited by 100
Omega-3 fatty acids and the treatment of depression: a review of scientific evidence
Wani, A. L., Bhat, S. A., & Ara, A. (2015) · Integrative Medicine Research · doi:10.1016/j.imr.2015.07.003 · Cited by 97
Anti-inflammatory treatment in schizophrenia
Müller, N., Myint, A.-M., Krause, D., Weidinger, E., & Schwarz, M. J. (2013) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2012.11.008 · Cited by 89
N-3 Polyunsaturated Fatty Acids through the Lifespan: Implication for Psychopathology
Pusceddu, M. M., Kelly, P., Stanton, C., Cryan, J. F., & Dinan, T. G. (2016) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyw078 · Cited by 70
Inflammation: good or bad for ADHD?
Donev, R., & Thome, J. (2010) · ADHD Attention Deficit and Hyperactivity Disorders · doi:10.1007/s12402-010-0038-7 · Cited by 54
Effects of Omega-3 in the treatment of violent schizophrenia patients
Qiao, Y., Mei, Y., Han, H., Liu, F., Yang, X. M., Shao, Y., Xie, B., & Long, B. (2018) · Schizophrenia Research · doi:10.1016/j.schres.2017.08.026 · Cited by 39
Metadata
- Authors
- Fenton, W. S., Dickerson, F., Boronow, J., Hibbeln, J. R., & Knable, M.
- Venue
- American Journal of Psychiatry
- Published
- 2001-12-01
- Volume
- 158
- Issue
- 12
- Pages
- 2071-2074
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W2131417790
- Cited by
- 323
- References
- 9
- FWCI
- 8.92
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.